Virtu Financial LLC acquired a new position in McKesson Co. (NYSE:MCK – Free Report) during the 2nd quarter, HoldingsChannel.com reports. The fund acquired 7,135 shares of the company’s stock, valued at approximately $4,167,000.
A number of other institutional investors have also recently bought and sold shares of the business. LRI Investments LLC purchased a new position in shares of McKesson in the 1st quarter worth about $28,000. Register Financial Advisors LLC purchased a new stake in shares of McKesson during the 1st quarter worth approximately $29,000. Sachetta LLC bought a new stake in shares of McKesson in the 4th quarter worth approximately $27,000. Newbridge Financial Services Group Inc. lifted its stake in McKesson by 333.3% in the first quarter. Newbridge Financial Services Group Inc. now owns 65 shares of the company’s stock valued at $35,000 after purchasing an additional 50 shares during the last quarter. Finally, Richardson Financial Services Inc. bought a new position in McKesson during the fourth quarter valued at $31,000. Institutional investors own 85.07% of the company’s stock.
McKesson Price Performance
MCK opened at $519.82 on Tuesday. The stock’s 50 day simple moving average is $565.94 and its 200 day simple moving average is $557.75. The firm has a market cap of $67.41 billion, a price-to-earnings ratio of 23.23, a PEG ratio of 1.18 and a beta of 0.44. McKesson Co. has a 1 year low of $422.15 and a 1 year high of $637.51.
McKesson Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 1st. Shareholders of record on Monday, September 2nd will be given a dividend of $0.71 per share. This is a positive change from McKesson’s previous quarterly dividend of $0.62. The ex-dividend date is Friday, August 30th. This represents a $2.84 dividend on an annualized basis and a yield of 0.55%. McKesson’s dividend payout ratio is presently 12.69%.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on the company. Mizuho upped their price target on McKesson from $540.00 to $570.00 and gave the company a “neutral” rating in a research report on Thursday, August 8th. Wells Fargo & Company cut their target price on McKesson from $576.00 to $535.00 and set an “equal weight” rating for the company in a research note on Friday. Evercore ISI lowered their price target on shares of McKesson from $660.00 to $630.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Bank of America boosted their price objective on shares of McKesson from $590.00 to $670.00 and gave the company a “buy” rating in a research note on Tuesday, June 25th. Finally, Robert W. Baird cut their price target on shares of McKesson from $694.00 to $671.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $620.93.
Check Out Our Latest Report on McKesson
Insider Transactions at McKesson
In other news, CEO Brian S. Tyler sold 3,753 shares of the firm’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $626.03, for a total value of $2,349,490.59. Following the completion of the sale, the chief executive officer now directly owns 82,339 shares of the company’s stock, valued at approximately $51,546,684.17. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last three months, insiders have sold 11,259 shares of company stock worth $6,635,492. 0.11% of the stock is currently owned by insiders.
About McKesson
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
Featured Articles
- Five stocks we like better than McKesson
- When to Sell a Stock for Profit or Loss
- Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
- ESG Stocks, What Investors Should Know
- Airline Stocks Off the Beaten Path: 3 Key Picks for Investors
- What is a Stock Market Index and How Do You Use Them?
- Why Rate Cuts Could Trigger a ‘Sell the News’ Event for Stocks
Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Co. (NYSE:MCK – Free Report).
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.